ArticleDigestive diseases and sciences2019
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab.
Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders.Biomolecules · 2023Pooled it
- Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Intestinal ultrasound findings and their prognostic value in patients with eosinophilic gastroenteritis.The World Allergy Organization journal · 2026Article
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort.Journal of pediatric gastroenterology and nutrition · 2026Article
- Effect of Biologics against Interleukin-5 Administered to Patients with Eosinophilic Gastroenteritis.Internal medicine (Tokyo, Japan) · 2025Article
- Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases.Gastroenterology & hepatology · 2025Article
- [Research progress on risk factors for poor prognosis in pediatric non-esophageal eosinophilic gastrointestinal disorder].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Achievement of duodenal ulcer remission by vedolizumab in children with eosinophilic gastroenteritis.Clinical journal of gastroenterology · 2025Article
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025Review
- Article
- Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report.Intestinal research · 2025Article
- CART-induced eosinophilic colitis with good response to corticosteroids and infliximab: a case report.Therapeutic advances in medical oncology · 2025Article
- Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review.Journal of clinical medicine · 2024Review
- Endoscopic Features of Eosinophilic Gastrointestinal Diseases.Immunology and allergy clinics of North America · 2024Review
- [Clinical characteristics of 267 children with eosinophilic gastrointestinal disease: a multicenter study].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Successful Treatment of Eosinophilic Enterocolitis in an Adult Patient With Adalimumab.ACG case reports journal · 2024Article
- Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases.Alimentary pharmacology & therapeutics · 2024Review
- Long-term prognosis and its associated predictive factors in patients with eosinophilic gastroenteritis.World journal of gastroenterology · 2024Article
- Eosinophilic gastroenteritis in an elderly men associated with antibiotic use post maxillofacial space infection: a case report.Frontiers in medicine · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEosinophilic gastroenteritis (EGE) is a rare, chronic inflammatory condition of the gastrointestinal tract. Little is known about its natural history and treatment outcomes. The aims of our analysis were to describe clinical presentation, response to current medical treatments, and to evaluate the response of refractory EGE to anti-integrin therapy.
methodsPatients with confirmed diagnosis of EGE fulfilling the diagnostic criteria: (1) the presence of gastrointestinal symptoms, (2) dense eosinophilic infiltration of the gastrointestinal mucosa, and (3) exclusion of other conditions leading to gastrointestinal eosinophilia were included in this analysis. In patients non-responding to corticosteroids and/or anti-TNF treatment the integrin blocker vedolizumab was used.
resultsEGE patients (n = 22) were predominantly female (63%) with a median age at diagnosis of 41.5 years. The most frequent symptoms were abdominal pain (100%), diarrhea (59%), nausea/vomiting (36%), and bloating (27%). No pathognomonic endoscopic alterations were found. Eosinophilic infiltration was observed in the majority of patients in more than one segment. Patients were treated with systemic steroids, topical, and enteral release steroids in 21/22 (95%) patients, proton pump inhibitors in 7/22 (32%), TNFα inhibitors in 3/22 (14%), and vedolizumab in 4/22 (18%) patients. In 3/4 of steroid-refractory patients vedolizumab induced a clinical and histological improvement.
conclusionsThe combination of highly variable clinical presentation, subtle endoscopic abnormalities, and involvement of several GI segments undermines the difficulty to diagnose EGE and the need for structured biopsy sampling. Corticosteroids were efficient in the majority of patients to induce remission. Response to the integrin blocker vedolizumab suggests further assessment in refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.